Mini Review
Accepted on 22 Aug 2025
Lower dose and weekly schedules of selinexor in multiple myeloma - updated evidence on safety and efficacy
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1649493
Type at least 3 characters
1,906 articles
Systematic Review
Published on 22 Aug 2025
CD20Ă—CD3 bispecific antibody achieved significant efficacy in patients with large B-cell lymphoma relapsing after or refractory to CAR-T therapy: a systematic review and meta-analysis
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1641769
- 245 views
Case Report
Accepted on 20 Aug 2025
Efficacy of Brentuximab Vedotin Combined with Sindilizumab in Relapsed/Refractory DLBCL Patient with Secondary Hemophagocytic Syndrome: A Case Report and Literature Review
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1531713
- 119 views
Perspective
Accepted on 20 Aug 2025
Overcoming barriers when introducing flow cytometry workflows in low resource settings
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1604295
Case Report
Published on 20 Aug 2025
Extramedullary relapse of acute lymphoblastic leukemia treated with a CAR-T cell therapy bridge to unrelated cord blood transplantation: a case report and review of the literature
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1508676
- 472 views
Case Report
Published on 20 Aug 2025
Case Report: Diagnosis of splenic marginal zone lymphoma by ultrasound and contrast- enhanced ultrasound
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1569962
- 445 views
Review
Published on 20 Aug 2025
TP53-mutated MDS and AML: immune dysregulation, tumor microenvironment, and emerging therapeutic strategies
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1655486
- 514 views
Case Report
Accepted on 19 Aug 2025
Case Report: Posterior Reversible Encephalopathy Syndrome (PRES) after CD19 Chimeric Antigen Receptor Therapy (CAR-T) for B-Acute Lymphoblastic Leukemia (B-ALL)
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1639892
- 238 views
Original Research
Accepted on 19 Aug 2025
Risk Factors for Thrombotic Events in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: A Retrospective Analysis of 336 Cases
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1639250
- 103 views
Case Report
Accepted on 19 Aug 2025
Histiocytic sarcoma as transdifferentiation of a marginal zone lymphoma – a case presentation based on post mortem examination and review of the literature
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1609694
Original Research
Published on 19 Aug 2025
Real-world Australian experience with tisagenlecleucel for relapsed/refractory diffuse large B-cell lymphoma—importance of pre-CAR-T optimization
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1633644
- 466 views
Case Report
Published on 18 Aug 2025
Obinutuzumab combined with bendamustine for the treatment of hairy cell leukemia variant: a case report and literature review
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1635856
- 348 views
Original Research
Accepted on 15 Aug 2025
Real-world data on adult AML with FLT3-ITD mutation from the Thai Acute Leukemia Working Group (TALWG)
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1606943
Case Report
Accepted on 14 Aug 2025
Erdheim-Chester Disease: Unveiling Hidden Manifestations through Two Case Reports
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1611907
Case Report
Accepted on 14 Aug 2025
Case Report: Transformation of Natural Killer-cell Large Granular Lymphocytic Leukemia (NK-LGLL) to Aggressive Natural Killer Cell Leukemia (ANKL)
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1648711
- 127 views
Original Research
Published on 13 Aug 2025
Implementing comprehensive geriatric assessment in an academic hematologic outpatient setting: experiences from medical doctors and patients
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2025.1570889
- 350 views